TP9.2.2Evaluating the Outcomes of anal squamous cell carcinoma (ASCC) with curative intent- a 10-year experience

Abstract

Abstract Background Our 10-year experience with radical treatment of patients with ASCC. Patients and Method Data of patients with ASCC treated with curative intent were analysed between January 2011 and December 2019. Patients underwent the standard workup, treated and followed up accordingly. The outcome measures were response to radical chemoradiotherapy, recurrent disease, disease-free and overall survival. Results 117 patients were diagnosed with anal cancer. 26 ASCC patients palliatively treated, adenocarcinoma(11), melanoma(1), Paget disease(1) and carcinoid(1) were excluded. Median age of included patients was 65(38-90) years with a male to female ratio of 1:1.9. Three patients were HIV positive and 52% of the patients had AIN of varying degree of dysplasia. AJCC stages were I(16), II(18), IIIA(19), IIIB(9) and IV(15). 88.3%%(68/77) of the patients had radical chemoradiotherapy while 9 patients with tumours ≤2cm underwent wide local excision. 92.6%(63/68) of the patients treated with radical chemoradiotherapy had complete response while 7.4%(5/77) had partial response. Four patients with incomplete response underwent salvage APER. 13%(10/77) of the patients developed recurrent disease. Mean survival time was 99.82(95% CI 88.87-110.77) months with 5-year overall survival rate of 78.0%. The mean disease-free survival time was 111.82(95% CI 102.38-121;26) months. 75.3%(58/77) of the patients were alive at the end of the study with an overall mortality rate was 24.7% and disease-specific mortality was 15.6%. Conclusion ASCC responds well to radical chemoradiotherapy with favourable outcome but locoregional failure and distant metastases are still issues.